Mallinckrodt divests non-core point-of-care blood testing
This article was originally published in Clinica
Executive Summary
Mallinckrodt is to sell its point-of-care blood testing equipment company, HemoCue, to a group of private equity funds, led by EQT Scandinavia BV, for an undisclosed amount. Mallinckrodt has three main product groups - respiratory, imaging and pharmaceuticals - and no longer considers its blood testing unit to be core business.